EIKN Eikon Therapeutics, Inc.

Price Chart

Executive Summary

Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing a 63.1% ORR and 90.8% DCR across 65 evaluable patients, with a manageable safety profile supporting outpatient administration. Initial Phase 1/2 data for EIK1003 (PARP1 inhibitor) showed a 24.5% ORR in combination with paclitaxel in heavily pretreated patients, though the stock has historically declined ~12% on prior neutral filings, suggesting limited market enthusiasm for early-stage data without a clear regulatory catalyst.

Actionable Insight

Key Facts

• EIK1001 (TeLuRide-005) Phase 2: 63.1% ORR and 90.8% DCR in 65 evaluable first-line NSCLC patients (non-squamous and squamous cohorts).
• EIK1001 safety profile: most TEAEs Grade 1-2; Grade 3+ TRAEs included neutropenia (30.6%), anemia (9.7%), thrombocytopenia (9.7%); all CRS events Grade 1-2.
• EIK1003 (Phase 1/2) monotherapy: 14.3% ORR overall, 26.7% in PARP-naïve patients; median DOR 7.8 months in 5 confirmed responders.
• EIK1003 + paclitaxel (Cohort 1C): 24.5% ORR in 53 evaluable patients (29.6% in platinum-resistant ovarian, 19.2% in breast cancer); 92% of responders had prior taxane therapy.
• No financial data (revenue, EPS, guidance) reported in this press release.
• Company is a late-stage clinical biopharma with no approved products; market cap ~$587M.

Financial Impact

No financial data provided; clinical data updates only.

Risk Factors

• EIK1001 and EIK1003 are investigational and may fail in later-stage trials.
• No revenue or approved products; company requires substantial additional funding.
• Competitive landscape: multiple TLR agonists and PARP inhibitors in development.
• Historical stock performance shows negative drift on prior neutral filings (~12% at T+20).

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status